個案資料
了解個案內容與學習目標，選擇授課教師及使用課程。
Turing Pharmaceuticals: The Ethics of Drug Pricing
內容大綱
In 2015 there was a public outcry over the price increase in Daraprim (pyrimethamine) by Turing Pharmaceuticals AG (Turing). Daraprim was a drug that was widely used by a small population of U.S. patients to treat toxoplasmosis. Soon after Turing acquired its commercialization rights in August 2015, the company increased the list price of the drug by over 5,000 per cent. The increase led to consumer protests in the United States, and the media vehemently condemned Turing’s action of raising the price for the decades-old drug that had gone off-patent in 1970. Later, the U.S. Congress stepped in, demanding that Turing’s officials clarify how they could justify the high price of Daraprim. How should Turing respond to the public outcry? Should Turing stand by the increased price for Daraprim? How could it handle the outcry from the patient groups that needed Daraprim?
學習目標
The case can be used at the undergraduate and MBA level in courses about business ethics, pricing policies, and the regulatory role played by governments. Using the case, students will have the opportunity to do the following:<br><ul><li>Discuss how pharmaceutical companies struggle to maintain a balance between doing good for their investors and for their consumers.</li><li>Understand the role played by the government and quasi-government agencies in addressing societal issues.</li><li>Discuss the role of fairness in pricing.</li><li>Discuss and debate the concepts of legality and ethics.</li></ul>